Glycoprotein / GP (virus)

Glycoprotein / GP (virus) Informations sur la molécule

Nom anglaisEnvelope glycoproteinNombre de médicaments commercialisés2
Nombre de médicaments cliniques2Alias de la cibleGP1,2,GP,Envelope glycoprotein
Phase de R&D la plus avancéeApproved
Nom anglaisEnvelope glycoprotein
Alias de la cibleGP1,2,GP,Envelope glycoprotein
Nombre de médicaments commercialisés2
Nombre de médicaments cliniques2
Phase de R&D la plus avancéeApproved

Demande de produit

Glycoprotein / GP (virus)Contexte de la molécule

EBOV encodes seven structural proteins: nucleoprotein (NP), polymerase cofactor (VP35), (VP40), GP, transcription activator (VP30), VP24, and RNA polymerase (L). GP protein contains 160-kDa envelope-attached glycoprotein (GP) and a 110 kDa secreted glycoprotein (sGP). GP is a class I fusion protein which assembles as trimers on viral surface and plays an important role in virus entry and attachment. Mature GP is a disulfide-linked heterodimer formed by two subunits, GP1 and GP2, which are generated from the proteolytical process of GP precursor (pre-GP) by cellular furin during virus assembly . GP1 is responsible for binding to the receptor(s) on target cells. Interacts with CD209/DC-SIGN and CLEC4M/DC-SIGNR which act as cofactors for virus entry into the host cell. GP2 acts as a class I viral fusion protein. GP1,2 mediates endothelial cell activation and decreases endothelial barrier function. sGP seems to possess an anti-inflammatory activity as it can reverse the barrier-decreasing effects of TNF alpha.

Glycoprotein / GP (virus)Alias de la molécule

GP,Envelope glycoprotein,GP(1,2)

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
Porgaviximab/Larcaviximab/Cosfroviximabc2G4-N; c4G7; c13C6Phase 3 ClinicalMapp Biopharmaceutical, Public Health Agency Of Canada'S National Microbiology LaboratoryHemorrhagic Fever, Ebola
Details
MIL-77MIL-77Phase 1 ClinicalBeijing Mabworks Biotech Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd, Institute Of Basic Medicine Academy Of Military Medical SciencesHemorrhagic Fever, Ebola
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
AnsuvimabVRC-EBOMAB092-00-AB; MAb114; MAb-114ApprovedNational Institute Of Allergy And Infectious Diseases (Niaid), National Institute of Health, IslamabadEbangaUnited StatesHemorrhagic Fever, EbolaRidgeback Biotherapeutics Lp2020-12-21Hemorrhagic Fever, Ebola
Details
Atoltivimab/Maftivimab/OdesivimabREGN3470-3471-3479; REGN-EB3ApprovedRegeneron Pharmaceuticals IncInmazebUnited StatesHemorrhagic Fever, EbolaRegeneron Pharmaceuticals Inc2020-10-14Hemorrhagic Fever, Ebola
Details
  • Informations sur la molécule
  • Demande de produit
  • Informations sur les médicaments commercialisés
  • Informations sur les médicaments cliniques